Nasdaq

SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis

- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ...
Monthly Prescribing Reference

Skyrizi Now Available as a Single-Dose Injection for Plaque Psoriasis

Skyrizi ® (risankizumab-rzaa) is now available as a single-dose 150mg prefilled pen or syringe for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic ...
FiercePharma

AbbVie launches new Skyrizi commercial after topping TV drug ad spenders’ ranking in July

AbbVie continues to be top of the TV drug ad spenders as its immunology blockbuster Skyrizi dominates this year’s iSpot roundup. After taking the top spot again last month, the Big Pharma is running ...
Nasdaq

AbbVie's (ABBV) Skyrizi Gets Nod for Psoriatic Arthritis in EU

AbbVie, Inc. ABBV announced that the European Commission (EC) approved its drug Skyrizi (risankizumab) for a second indication, which is active psoriatic arthritis. The EC approval is for subcutaneous ...
FiercePharma

AbbVie's Skyrizi nabs psoriatic arthritis nod, its 2nd, shortly after Rinvoq

After Rinvoq won two new indications in as many months, AbbVie's immunology compatriot Skyrizi is getting in on the approval action. Skyrizi clinched a second nod, this time to treat adults with ...